Login

Balance Sheets

In millions of USD, except per-share amounts
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Assets
Cash in escrow
Prepaid expenses
Deferred offering costs
Due from Sponsor
Total current assets
Noncurrent assets:
Marketable securities
Total noncurrent assets
Total assets
Liabilities and shareholders’ deficit
Current liabilities:
Accrued liabilities
Due to Sponsor
Other payable
Promissory note payable to Sponsor
Total current liabilities
Deferred underwriting commissions
Deferred underwriting commissions
Total noncurrent liabilities
Total liabilities
Ordinary shares subject to possible redemption, 2,502,021 and 6,900,000 shares at redemption value of $11.12 and $10.44 per share, respectively, including interest and dividends earned in Trust Account
Shareholders’ deficit:
Ordinary shares, $0.001 par value; 50,000,000 shares authorized; and 2,032,000 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
Additional paid-in capital
Accumulated deficit
Total shareholders’ deficit
Total liabilities and shareholders’ deficit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support